higher risk of clotting as well as an increased risk of stent/device subsequent thrombosis. There is an ongoing search for inflammatory biomarkers that can help determine at-risk individuals. Coronary "microembolization" is being explored as a focal point for coronary thrombus formation and subsequent sudden death due to acute myocardial infarction. High mobility group box-1 (HMGB-1) proteins as important mediators in thrombus formation. Coronary sinus thrombosis as a severe complication after procedures. The coronary sinus is the venous counterpart to the coronary arteries, where de-oxygenated blood returns from heart tissue. A large thrombus here slows overall blood circulation to heart tissue as well as may mechanically compress a coronary artery. Diagnosis Clinical signs of MI or angina if coronary thrombus is symptomatic: Imaging modalities used to evaluate the presence of coronary thrombi: angioscopy endocoronary ultrasound coronary angiography magnetic resonance imaging (MRI) Postmortem examiners may look for Lines of Zahn, to determine whether blood clotted in the heart vessels before or after death. Management Management of symptomatic coronary thrombosis follows established treatment algorithms for myocardial infarction.Treatment options include: emergency coronary artery bypass grafting (CABG) stent implantation intracoronary thrombolysis anticoagulation with heparin or glycoprotein IIb/IIIa inhibitors thrombus aspiration as reperfusion strategy platelet P2Y12 receptor inhibitors: The CURE trial in 2001 determined that the addition of clopidogrel showed a positive effect on cardiovascular mortality, non-fatal MI, and stroke at the cost of an increased risk of major bleeding. To address the possibility of identifying and treating asymptomatic coronary artery disease to prevent development of coronary thrombosis, the COURAGE trial was published in 2018. It determined that preemptive treatment with percutaneous coronary intervention (PCI) did not lead to a difference in death or myocardial infarction over a 15-year period. There are numerous treatments currently being studied for management and prevention of coronary thrombosis. Statin drugs, in addition to their primary cholesterol-lowering mechanisms of action, have been studied to target a number of pathways that may decrease coronary inflammation and subsequent thrombosis. Another realm of potential treatments in early stages of adoption is in therapeutic use of contrast ultrasound on thrombus dissolution. Notable people Terminology Thrombosis is defined as the formation of a thrombus (blood clot) inside a blood vessel, leading to obstruction of blood flow within the circulatory system. Coronary thrombosis refers to the formation and presence of thrombi in the coronary arteries of the heart. Note that the heart does not contain veins, but